Free Trial
OTCMKTS:ALSE

Alseres Pharmaceuticals (ALSE) Stock Price, News & Analysis

Alseres Pharmaceuticals logo
$0.0050 0.00 (0.00%)
As of 10/18/2024

About Alseres Pharmaceuticals Stock (OTCMKTS:ALSE)

Key Stats

Today's Range
$0.0050
▼
$0.0050
50-Day Range
$0.0050
▼
$0.0050
52-Week Range
$0.0050
▼
$0.0050
Volume
N/A
Average Volume
N/A
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Alseres Pharmaceuticals, Inc. was a biotechnology company focused on developing diagnostic imaging agents and therapeutic products for disorders of the central nervous system. Its research programs addressed conditions including Parkinson’s disease, attention-deficit hyperactivity disorder and spinal cord injury.

The company’s principal development program was Altropane, a molecular imaging agent designed to target dopamine transporters in the brain. The technology was investigated for its potential use in imaging-related research and the evaluation of neurological disorders. Alseres also pursued Cethrin, an experimental biologic intended to support recovery following spinal cord injury.

Alseres was formerly known as Boston Life Sciences, Inc. and was based in the United States. Publicly available information about the company’s current operations, leadership and geographic activities is limited.

AI Generated. May Contain Errors.

Receive ALSE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Alseres Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

ALSE Stock News Headlines

FTSE 350 Pharmaceuticals & Biotechnology (FTNMX201030)
Your book is inside
The "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. They don't know the rules. They don't know what to avoid. And they hand their account to Wall Street on a silver platter. Normally $29.97. Free today.tc pixel
Contrast Agents Market Growth by 2031
See More Headlines

ALSE Stock Analysis - Frequently Asked Questions

Alseres Pharmaceuticals' stock was trading at $0.0050 at the beginning of 2026. Since then, ALSE stock has increased by 0.0% and is now trading at $0.0050.

Company Calendar

Today
10/16/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Industry
Pharmaceuticals
Sub-Industry
Pharmaceuticals
Current Symbol
OTCMKTS:ALSE
CIK
N/A
Employees
3
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
N/A
Quick Ratio
N/A

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
N/A
Price / Book
N/A

Miscellaneous

Outstanding Shares
N/A
Free Float
N/A
Market Cap
N/A
Optionable
Not Optionable
Beta
N/A
 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

This page (OTCMKTS:ALSE) was last updated on 10/18/2024 by MarketBeat.com Staff.
From Our Partners